secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016809
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M
-------------------------------------------------------------------------------

- Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).
- Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.
- Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.
- Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.
- Co-CEOs cite customer base expansion and revenue growth from core business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/0001437749-25-016809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774925016809/inbp20250417_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer